Specialized Pro-Resolving Mediators (SPMs) and Inflammation Resolution
Current understanding
Specialized pro-resolving mediators (SPMs — resolvins, protectins, maresins, lipoxins) are ω-3-derived lipid mediators proposed to actively terminate acute inflammation and restore tissue homeostasis, positioning failed resolution (rather than excess initiation) as a distinct mechanistic axis of inflammaging. Preclinical animal-model [animal-model] work supports resolution-agonist effects on vascular endothelial function, macrophage polarization, and metabolic inflammation, but human translation is early: oral SPM supplementation is only now entering small hypothesis-testing RCTs in cardiometabolic populations [human-rct, protocol-only, no efficacy results]. The gap between resolution-pharmacology biology and consumer/therapeutic SPM narratives is large.
Evidence log
- 2026-07-11 — Chronic subdural hematoma as failed resolution at the aged dura-subdural interface: Immune-vascular mechanisms, biomarker interpretation, and therapeutic translation.: cross-connection with chronic-subdural-hematoma-geroscience: Framing CSDH as failed resolution at the aged dura-subdural interface explicitly ties a neurosurgical age-related disease to the SPM/inflammation-resolution pharmacology axis as a candidate biomarker/therapy direction. (novelty: 3)
- 2026-06-19 — Epigenetic Gene Networks Governing Immune State Transitions Across the Lifespan.: cross-connection with epigenetic-immune-transition-windows: Resolution failure in inflammation (the biological gap SPMs target) is reframed as a specific instance of a narrowed epigenetic transition window preventing the pro-inflammatory → pro-resolving state switch in aged immune cells. (novelty: 3)
- 2026-09-14 — The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients: cross-connection with inflammaging: Positions failed inflammation resolution as a distinct mechanistic axis of inflammaging that is directly targetable by exogenous SPM supplementation, separating ‘less inflammatory initiation’ from ‘more active termination’ as therapeutic categories. (novelty: 3)